Actively Recruiting
Evaluation of Acalabrutinib with Rituximab in Untreated Elderly and Frail Patients with Diffuse Large B-Cell Lymphoma
Led by AstraZeneca · Updated on 2026-10-30
80
Participants Needed
57
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of acalabrutinib combined with rituximab in elderly andor frail patients with diffuse large B-cell lymphoma DLBCL who have not received prior treatment and are not suitable for standard chemotherapy. This phase II, open-label, single-arm study focuses on patients aged 65 and older, targeting those who are either over 80 or between 65 and 79 but ineligible for standard chemoimmunotherapy. Participants will receive oral acalabrutinib starting on Cycle 1 Day 1 for up to 28 cycles or until disease progression or other criteria lead to stopping treatment. Rituximab will be given intravenously on Cycle 1 Day 15 and by subcutaneous injection from Cycle 2 through Cycle 8. The treatment phase includes up to 8 cycles of rituximab and up to 28 cycles of acalabrutinib. The study lasts up to 108 weeks, including up to 28 days for screening and 104 weeks for treatment and follow-up. Researchers will monitor adverse events of Grade 3 to 4 severity, response rates, survival outcomes, and physical function using tests like the Timed Up and Go. Safety and efficacy will be assessed throughout treatment and up to 3.5 years after starting, with ongoing monitoring of disease status and patient health.
CONDITIONS
Brief Title
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here